{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biweekly+FOLFIRI", "query": { "intervention": "Biweekly FOLFIRI" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 47, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biweekly+FOLFIRI&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T13:10:04.213Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01653470", "title": "Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "5-Fluorouracil (5FU)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "BMS-906024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2012-10-12", "completion_date": "2017-05-08", "has_results": false, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01653470" }, { "nct_id": "NCT01322815", "title": "A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "chemotherapy and GI-4000", "type": "DRUG" }, { "name": "GI-4000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-10", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-08-15", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322815" }, { "nct_id": "NCT01183494", "title": "A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI, Avastin, Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-12-12", "completion_date": "2017-06-02", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183494" }, { "nct_id": "NCT00077233", "title": "FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2003-12", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2018-05-16", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 77, "location_summary": "Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077233" }, { "nct_id": "NCT02833753", "title": "Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Appendix Cancer", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 14, "start_date": "2016-07", "completion_date": "2022-02", "has_results": false, "last_update_posted_date": "2022-05-31", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02833753" }, { "nct_id": "NCT06252649", "title": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI Regimen", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Bevacizumab-awwb", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-07-17", "completion_date": "2032-04-25", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 26, "location_summary": "Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06252649" }, { "nct_id": "NCT01941173", "title": "Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-07-21", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 3, "location_summary": "Duarte, California • Lancaster, California • South Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01941173" }, { "nct_id": "NCT02508077", "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Colorectal Carcinoma", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-02-16", "completion_date": "2017-09-13", "has_results": true, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 4, "location_summary": "Duarte, California • Lancaster, California • Rancho Cucamonga, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02508077" }, { "nct_id": "NCT00101686", "title": "Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Modified Bolus 5-FU/LV with Irinotecan", "type": "DRUG" }, { "name": "FOLFIRI + bevacizumab", "type": "DRUG" }, { "name": "miFL + bevacizumab", "type": "DRUG" }, { "name": "Infusional 5-FU/LV with Irinotecan", "type": "DRUG" }, { "name": "Oral Capecitabine with Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 547, "start_date": "2003-02", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2010-01-12", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 141, "location_summary": "Birmgingham, Alabama • Birmingham, Alabama • Birmngham, Alabama + 123 more", "locations": [ { "city": "Birmgingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmngham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101686" }, { "nct_id": "NCT01765582", "title": "Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 280, "start_date": "2013-01-23", "completion_date": "2016-03-14", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-09-02T13:10:04.213Z", "location_count": 45, "location_summary": "Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01765582" } ] }